☆ 4.1 Article

Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu et al.

Summary: This study analyzed tumor samples from patients with hepatocellular carcinoma and found that combination therapy with atezolizumab and bevacizumab was effective in treating this type of cancer. Patients with high expression of VEGF Receptor 2, regulatory T cells, and myeloid inflammation signatures showed better outcomes with the combination therapy compared to atezolizumab alone. These findings provide insights into baseline immune and genetic features that can identify patients who will benefit from the combination therapy of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

NATURE MEDICINE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review

Florian P. Reiter et al.

Summary: The systemic treatment of hepatocellular carcinoma (HCC) is rapidly evolving due to emerging new treatment options, with several multi-kinase inhibitors and immune-checkpoint inhibitors approved for use in addition to the traditional sorafenib. The key question now is the optimal combination and sequence of these agents for treating patients with advanced HCC, while immune-checkpoint inhibitors-based treatment combinations could be extended to patients with intermediate-stage HCC for better objective response and survival outcomes.

DIGESTIVE DISEASES (2021)

Add to Collection

Article Oncology

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Landon C. Brown et al.

Summary: This multicenter study demonstrates significantly improved outcomes with ICI therapy in patients with P/LP versus VUS LRP1B alterations, regardless of TMB/MSI status. Further mechanistic and prospective validation studies are warranted.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Hanyu Rao et al.

Summary: This study reveals that SETD2 inhibits beta-catenin activity during the transition from polycystic kidney disease (PKD) to renal cell carcinoma (RCC) by competing with beta-catenin for binding promoters of target genes, ultimately enhancing Wnt/beta-catenin signaling and promoting epithelial-to-mesenchymal transition and tumorigenesis.

CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Karan Seegobin et al.

Summary: ICI therapy in NSCLC shows promising outcomes in certain cases with actionable mutations, but its efficacy remains unclear in other cases. The correlation between PD-L1 expression or tumor mutation burden and treatment outcome is inconclusive.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy

Mingdong Lu et al.

Summary: SETD2 mutation leads to higher tumor mutation burden and microsatellite instability, affects the transcription of immune-related genes, and is associated with favorable clinical outcomes in cancer patients treated with immune checkpoint inhibitors.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

The effect of low frequency and low intensity ultrasound combined with microbubbles on the sonoporation efficiency of MDA-MB-231 cells

Qi Liu et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medical Laboratory Technology

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)

Add to Collection

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Genetics & Heredity

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert M. Samstein et al.

NATURE GENETICS (2019)

Add to Collection

Review Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Gastroenterology & Hepatology

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

Sandrine Boyault et al.

HEPATOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.